Mariner’s Denali Therapeutics DNLI Stock Holding History

Mariner’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$844K	Buy	32,799 +14,668	+81%	+$301K	﹤0.01%	2080
2026 Q1	$348K	Buy	+18,131	New	+$361K	﹤0.01%	2743

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner's DNLI Position: Q2 2026 in Review

Mariner increased its Denali Therapeutics (DNLI) stake by 81% in Q2 2026, buying an estimated $301K and bringing the position to 32,799 shares worth $844K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

Mariner first reported a position in DNLI in Q1 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Mariner held 32,799 shares of Denali Therapeutics worth $844K as of Q2 2026.
Mariner bought 14,668 Denali Therapeutics shares in Q2 2026, an estimated $301K.
Denali Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2080 holding.
Mariner first reported a position in Denali Therapeutics in Q1 2026 and has held it in 2 quarters since.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.